Please Wait.....
Report
Global Conjugate Vaccine Market Report and Forecast 2023-2031
Market Report I 2023-04-27 I 147 Pages I EMR Inc.
Global Conjugate Vaccine Market Report and Forecast 2023-2031
Global Conjugate Vaccine Market Outlook
The global conjugate vaccine market size attained a value of USD 16 billion in 2022. The market is anticipated to grow at a CAGR of 11% during the forecast period of 2023-2031 to attain a value of USD 40.9 billion by 2031.
Conjugate Vaccine Market: Introduction
A conjugate vaccine is a type of vaccine that is created by linking a protein or polysaccharide from a disease-causing bacterium or virus to a carrier molecule. This process creates a new molecule that the body's immune system recognizes as foreign and mounts an immune response against it. Conjugate vaccines are used to prevent bacterial infections, particularly in children, and are known to be highly effective.
The primary use of conjugate vaccines is to prevent bacterial infections caused by bacteria that have a polysaccharide capsule. These bacteria are difficult for the immune system to recognize and attack because they are coated with a polysaccharide layer that the immune system does not recognize as foreign. However, when the polysaccharide is linked to a carrier protein, the immune system recognizes it as a foreign invader and produces an immune response against it.
Some examples of bacterial infections that can be prevented with conjugate vaccines include meningitis, pneumonia, and sepsis caused by Streptococcus pneumoniae, Haemophilus influenzae type b (Hib), and Neisseria meningitidis. Conjugate vaccines are also used to prevent infections caused by the bacteria that cause diphtheria and tetanus.
Benefits of conjugate vaccines include:
- High efficacy: Conjugate vaccines are highly effective at preventing bacterial infections and have been shown to be more effective than other types of vaccines.
- Long-lasting protection: Conjugate vaccines provide long-lasting protection against bacterial infections, reducing the need for additional doses or boosters.
- Fewer side effects: Conjugate vaccines are known to have fewer side effects than other types of vaccines, making them a safe and effective option for immunization.
- Reduced healthcare costs: Conjugate vaccines can help reduce healthcare costs by preventing bacterial infections that require expensive medical treatment, hospitalization, and rehabilitation.
Overall, conjugate vaccines are an effective and safe way to prevent bacterial infections, particularly in children. They provide long-lasting protection, have few side effects, and can help reduce healthcare costs by preventing costly medical treatment. With the development of new conjugate vaccines, the prevention of bacterial infections is likely to continue to improve in the future.
conjugate Vaccine Market Segmentations
The market can be categorised into type, indications, pathogen type, patient type, end user, and region.
Market Breakup by Type
- Monovalent Conjugate Vaccines
- Multivalent Conjugate Vaccines
Market Breakup by Indications
- Pneumococcal Disease
- Influenza
- Meningococcal Disease
- Diphtheria Tetanus and Pertussis (DTP)
- Others
Market Breakup by Pathogen Type
- Bacterial Conjugate Vaccine
- Viral Conjugate Vaccine
- Combination (Viral and Bacterial)
Market Breakup by Patient type
- Pediatrics
- Adults
Market Breakup by End User
- Hospitals
- Clinics
- Homecare Settings
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Conjugate Vaccine Market Scenario
The global market for conjugate vaccine is a growing segment of the pharmaceutical industry, driven by increasing demand for effective vaccines to prevent bacterial infections. Conjugate vaccines are used to prevent bacterial infections caused by bacteria that have a polysaccharide capsule. They are particularly effective in preventing infections in children, and are used to prevent diseases such as meningitis, pneumonia, and sepsis caused by Streptococcus pneumoniae, Haemophilus influenzae type b (Hib), and Neisseria meningitidis.
The market for conjugate vaccines is expected to continue to grow at a steady pace, driven by several factors, including increasing awareness about the importance of vaccination, the development of new and innovative vaccines, and the increasing adoption of vaccines in emerging markets.
North America is the largest market for conjugate vaccines, owing to the high prevalence of bacterial infections and well-established healthcare infrastructure in the region. However, the Asia Pacific region is expected to witness significant growth in the coming years, driven by the increasing focus on healthcare development and rising demand for cost-effective medical devices. Countries like China and India are expected to be major contributors to this growth due to their large populations and increasing healthcare spending.
The market for conjugate vaccines is highly competitive, with many players offering a wide range of products to cater to the diverse needs of healthcare providers and patients. Some of the key players in the market include Pfizer, Merck & Co., Inc., GlaxoSmithKline plc, Sanofi Pasteur, and Novartis International AG.
Overall, the conjugate vaccine market is expected to continue to grow at a steady pace, driven by the increasing demand for safe and effective healthcare delivery. With increasing awareness about the importance of vaccination and the development of new and innovative vaccines, the adoption of conjugate vaccines is likely to increase in the coming years, further fuelling the growth of the market.
Key Players in the Global Conjugate Vaccine Market
The report gives an in-depth analysis of the key players involved in the conjugate vaccine market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Merck & Co., Inc.
- Novartis AG
- Serum Institute of India Pvt. Ltd.
- Pfizer Inc.
- Sanofi
- Bharat Biotech
- Biological E
- GlaxoSmithKline plc.
- Astellas Pharma Inc.
- AstraZeneca
- SutroVax Inc.
- CSL Limited
- Bavarian Nordic
- Emergent BioSolutions Inc.
- Valneva SE
- Moderna, Inc.
- Novavax
- Johnson & Johnson Services, Inc.
- Themis Bioscience GmbH
- B. Braun Melsungen AG
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Conjugate Vaccines Market Overview
3.1 Global Conjugate Vaccines Market Historical Value (2016-2022)
3.2 Global Conjugate Vaccines Market Forecast Value (2023-2031)
4 Global Conjugate Vaccines Market Landscape
4.1 Global Conjugate Vaccines Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Conjugate Vaccines Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indications
4.2.3 Analysis by Pathogen Type
5 Global Conjugate Vaccines Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Conjugate Vaccines Market Segmentation
6.1 Global Conjugate Vaccines Market by Type
6.1.1 Market Overview
6.1.2 Monovalent Conjugate Vaccines
6.1.3 Multivalent Conjugate Vaccines
6.2 Global Conjugate Vaccines Market by Indications
6.2.1 Market Overview
6.2.2 Pneumococcal Disease
6.2.3 Influenza
6.2.4 Meningococcal Disease
6.2.5 Diphtheria Tetanus and Pertussis (DTP)
6.2.6 Others
6.3 Global Conjugate Vaccines Market by Pathogen Type
6.3.1 Market Overview
6.3.2 Bacterial Conjugate Vaccine
6.3.3 Viral Conjugate Vaccine
6.3.4 Combination (Viral and Bacterial)
6.4 Global Conjugate Vaccines Market by Patient Type
6.4.1 Market Overview
6.4.2 Pediatrics
6.4.3 Adults
6.5 Global Conjugate Vaccines Market by End User
6.5.1 Market Overview
6.5.2 Hospitals
6.5.3 Clinics
6.5.4 Homecare Settings
6.5.5 Others
6.6 Global Conjugate Vaccines Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Conjugate Vaccines Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Conjugate Vaccines Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Conjugate Vaccines Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Conjugate Vaccines Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Conjugate Vaccines Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Merck & Co., Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Novartis AG
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Serum Institute of India Pvt. Ltd.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Pfizer Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Sanofi
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Bharat Biotech
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Biological E
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 GlaxoSmithKline plc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Astellas Pharma Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 AstraZeneca
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 SutroVax Inc.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 CSL Limited
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Bavarian Nordic
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Emergent BioSolutions Inc.
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
18.15 Valneva SE
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.15.5 Certifications
18.16 Moderna, Inc.
18.16.1 Financial Analysis
18.16.2 Product Portfolio
18.16.3 Demographic Reach and Achievements
18.16.4 Mergers and Acquisitions
18.16.5 Certifications
18.17 Novavax
18.17.1 Financial Analysis
18.17.2 Product Portfolio
18.17.3 Demographic Reach and Achievements
18.17.4 Mergers and Acquisitions
18.17.5 Certifications
18.18 Johnson & Johnson Services, Inc.
18.18.1 Financial Analysis
18.18.2 Product Portfolio
18.18.3 Demographic Reach and Achievements
18.18.4 Mergers and Acquisitions
18.18.5 Certifications
18.19 Themis Bioscience GmbH
18.19.1 Financial Analysis
18.19.2 Product Portfolio
18.19.3 Demographic Reach and Achievements
18.19.4 Mergers and Acquisitions
18.19.5 Certifications
18.20 B. Braun Melsungen AG
18.20.1 Financial Analysis
18.20.2 Product Portfolio
18.20.3 Demographic Reach and Achievements
18.20.4 Mergers and Acquisitions
18.20.5 Certifications
19 Global Conjugate Vaccines Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security